Business UpdateJun 18, 2026, 08:07 AM
BioCardia Details 2026 Priorities, Japan PMDA Submission by Q4
AI Summary
BioCardia, Inc. issued a letter to shareholders outlining its business strategy, top priorities, and business development opportunities. A key focus is the planned submission for approval of its CardiAMP Cell Therapy for ischemic heart failure to Japan's PMDA by Q4 2026, targeting an initial 20,000 patients with potential reimbursement of $124,000 per procedure. The company is also advancing its CardiAMP HF II Trial in the US and pursuing partnerships for its Helix delivery system and allogeneic MSC therapy platforms. These milestones are expected to create compelling opportunities for value creation.
Key Highlights
- Top priority is submitting CardiAMP Cell Therapy for ischemic heart failure to Japan PMDA by Q4 2026.
- Initial Japan approval could target 20,000 patients with potential $124,000 reimbursement per procedure.
- Japan approval enables expedited registration in other "Reference Countries" and MDSAP audit acceptance.
- Driving enrollment for confirmatory CardiAMP HF II Trial in the USA, with 4 active study centers.
- Helix delivery system and Heart3D platform are therapeutic-agnostic, with 8 active discussions globally.
- Allogeneic MSC therapy platform has 2 FDA-approved INDs for cardiac and pulmonary indications.
- Recent capital raise supports Japan submission, US trial enrollment, and pipeline discussions.
Price Impact
More from BCDA